fumaric acid

DRUG2 trials

Sponsors

Jochen Schmitt., Novartis Pharmaceuticals

Conditions

Psoriasis

Phase 3

Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.

CompletedNCT02474082

Novartis PharmaceuticalsPsoriasis

Start: 2015-04-30End: 2016-06-30Updated: 2017-10-27

Unknown Phase

Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis

CompletedNCT01812954

Jochen Schmitt.Psoriasis

Start: 2013-03-31End: 2014-06-30Updated: 2017-08-11

Related Papers

A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment.

2019-11-1931 citations